<DOC>
	<DOCNO>NCT00265694</DOCNO>
	<brief_summary>1 . Recently radomized trial vinorelbine versus best supportive care patient 70 year age older demonstrate definite improvement overall survival rate quality life chemotherapy . 2 . The role combination therapy contain platinum compound , standard therapy young patient still vague . 3 . Gemcitabine carboplatin favorable toxicity profile .</brief_summary>
	<brief_title>Random Trial Elderly Patients With NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients pathologically confirm , advance ( clinical stage IIIB IV ) NSCLC No previous chemotherapy history Age ≥ 65 year ECOG performance status ≤ 2 Adequate marrow function ( ANC ≥ 2,000/mm3 , platelet ≥ 100,000/mm3 ) , renal liver function ( total bilirubin &lt; 2.0 mg/dL , AST/ALT level &lt; 3 × upper limit normal , serum creatinine &lt; 2.0 mg/dL ) Patients informed write consent Patients major illness ( active infection , severe heart disease , concomitant malignancy , etc )</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2005</verification_date>
</DOC>